Güner Savaş, Gökalp Mehmet Ata, Gözen Abdurrahim, Ünsal Seyyid Şerif, Güner Şükriye İlkay
Department of Trauma and Orthopedic Surgery, Medical School, Yuzuncu Yil University.
School of Health, Yuzuncu Yil University, Van, Turkey.
Ther Clin Risk Manag. 2016 Nov 14;12:1693-1699. doi: 10.2147/TCRM.S114707. eCollection 2016.
The intramuscular application of etofenamate in the treatment of knee osteoarthritis was not observed in the existing English language literature. The objectives of this study were to compare the efficacy of etofenamate versus hyaluronic acid (HA) in reducing joint pain and functional improvement for mild to moderate knee osteoarthritis. The patients were randomly divided into etofenamate (n=29) and HA (n=30) groups. Intramuscular etofenamate injection was administered as a series of seven intramuscular injections at intervals of 1 day. Intra-articular HA injection was administered as a series of three intra-articular injections at intervals of 1 week. Clinical evaluation was made before the first injection and again both 6 and 12 months after the last injection. The evaluation consisted of patient-assessed pain on a visual analog scale (VAS) and on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Statistical significance was found for the etofenamate group when comparing preinjection with 12 months postinjection VAS scores (<0.05). Statistical significance was also found for the HA group when comparing preinjection with 12 months postinjection VAS and WOMAC scores (<0.05). However, there was no significant difference between the etofenamate and HA groups in terms of VAS or WOMAC scores measured at 12 months after injection (>0.05). Results from this study indicated that, etofenamate treatment was not significantly more effective than HA treatment. However, both methods were effective and successful in treating knee osteoarthritis.
现有英文文献中未观察到依托芬那酯肌肉注射治疗膝骨关节炎的情况。本研究的目的是比较依托芬那酯与透明质酸(HA)在减轻轻至中度膝骨关节炎关节疼痛和改善功能方面的疗效。患者被随机分为依托芬那酯组(n = 29)和HA组(n = 30)。依托芬那酯肌肉注射为一系列七次肌肉注射,间隔1天。关节内注射HA为一系列三次关节内注射,间隔1周。在首次注射前以及最后一次注射后6个月和12个月进行临床评估。评估包括患者通过视觉模拟量表(VAS)以及西安大略和麦克马斯特大学骨关节炎指数(WOMAC)评估的疼痛情况。比较依托芬那酯组注射前与注射后12个月的VAS评分时发现有统计学意义(<0.05)。比较HA组注射前与注射后12个月的VAS和WOMAC评分时也发现有统计学意义(<0.05)。然而,在注射后12个月测量的VAS或WOMAC评分方面,依托芬那酯组和HA组之间没有显著差异(>0.05)。本研究结果表明,依托芬那酯治疗并不比HA治疗显著更有效。然而,两种方法在治疗膝骨关节炎方面均有效且成功。
Ther Clin Risk Manag. 2016-11-14
J Pharm Bioallied Sci. 2013-1
Am Fam Physician. 2011-6-1
J Manag Care Pharm. 2007-3
Clin Orthop Relat Res. 2006-5
Med J Aust. 2004-3-1
Ann Rheum Dis. 1957-12